MedPath

Altamira Therapeutics AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$2.9M
Website

Altamira Therapeutics Partners with Undisclosed Company to Advance Circular RNA Delivery Platform

Altamira Therapeutics has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore platform for delivering circular RNA payloads.

Altamira Therapeutics Partners with Radiopharmaceutical Company to Enhance Cancer Treatment Targeting

Altamira Therapeutics has entered into a collaboration agreement with an undisclosed radiopharmaceutical company to evaluate the use of its proprietary RNA delivery platform for enhanced cancer targeting.

© Copyright 2025. All Rights Reserved by MedPath